Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Mouse|
|Published species reactivity||Rat, Mouse|
|Host / Isotype||Mouse / IgG2b, kappa|
|Immunogen||Recombinant human p57Kip2 protein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50-1:100|
|Immunoprecipitation (IP)||2 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-14361 targets p57Kip2 in IHC (P) and IP applications and shows reactivity with Human and mouse samples.
The MA5-14361 immunogen is recombinant human p57Kip2 protein.
p57Kip2 (or CDKN1C) is a potent tight-binding inhibitor of several G1 cyclin complexes, and is a negative regulator of cell proliferation. The gene encoding human p57Kip2 is located on chromosome 11p15.5, a region implicated in both sporadic cancers, Wilm's tumor, and Beckwith-Wiedemann syndrome (BWS), a cancer syndrome, making it a tumor suppressor candidate. BWS is characterized by numerous growth abnormalities and an increased risk of childhood tumors. Several types of childhood tumors including Wilms' tumor, adrenocortical carcinoma and rhabdomyosarcoma display a specific loss of maternal 11p15 alleles, suggesting that genomic imprinting plays an important part. This region also contains two other imprinted genes, insulin-like growth factor II (IGF-II) and H19, both of which seem to be implicated in adrenal neoplasms.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
BAF200 is required for heart morphogenesis and coronary artery development.
MA5-14361 was used in immunohistochemistry to examine the role of BAF200 in both heart morphogenesis and coronary artery angiogenesis
|He L,Tian X,Zhang H,Hu T,Huang X,Zhang L,Wang Z,Zhou B||PloS one (9:null)||2014|
The notch target gene HES1 regulates cell cycle inhibitor expression in the developing pituitary.
MA5-14361 was used in immunohistochemistry to study the role of the Notch target gene HES1 in regulating cell cycle inhibitor expression in the developing pituitary
|Monahan P,Rybak S,Raetzman LT||Endocrinology (150:4386)||2009|
Distinct developmental roles of cell cycle inhibitors p57Kip2 and p27Kip1 distinguish pituitary progenitor cell cycle exit from cell cycle reentry of differentiated cells.
MA5-14361 was used in immunohistochemistry to study the roles of p57Kip2 and p27Kip1 in the control of cell proliferation during organogenesis in the pituitary
|Bilodeau S,Roussel-Gervais A,Drouin J||Molecular and cellular biology (29:1895)||2009|
Severe feto-placental abnormalities precede the onset of hypertension and proteinuria in a mouse model of preeclampsia.
MA5-14361 was used in immunohistochemistry to study early feto-placental abnormalities before the onset of maternal disease in a mouse model of preeclampsia
|Dokras A,Hoffmann DS,Eastvold JS,Kienzle MF,Gruman LM,Kirby PA,Weiss RM,Davisson RL||Biology of reproduction (75:899)||2006|
BMP10 is essential for maintaining cardiac growth during murine cardiogenesis.
MA5-14361 was used in immunohistochemistry to investigate the role of BMP10 in cardiac development
|Chen H,Shi S,Acosta L,Li W,Lu J,Bao S,Chen Z,Yang Z,Schneider MD,Chien KR,Conway SJ,Yoder MC,Haneline LS,Franco D,Shou W||Development (Cambridge, England) (131:2219)||2004|
Expression and activity of the CDK inhibitor p57Kip2 in chondrocytes undergoing hypertrophic differentiation.
MA5-14361 was used in western blot to investigate the role of p57Kip2 in the process of chondrocyte differentiation
|Stewart MC,Kadlcek RM,Robbins PD,MacLeod JN,Ballock RT||Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (19:123)||2004|
Cyclin-dependent kinase inhibitor 1C; cyclin-dependent kinase inhibitor 1C (p57, Kip2); Cyclin-dependent kinase inhibitor p57; p57Kip2
AL024410; BWCR; BWS; CDKI; CDKN1C; KIP2; p57; p57(kip2); p57Kip2; WBS